Nouvelle déclaration d'incident
No de la demande: 2023-4163
Numéro de référence du titulaire d'homologation: 2023-CA-000267
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: MANITOBA
ARLA No d'homologation 30728 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard Pro Drops for Dogs 6 - 14 kg Spot-on
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Dog / Chien
Shih Tzu/Yorkshire Terrier crossbred
1
Homme
2
4.0
kg
Cutanée
>15 min <=2 hrs / >15 min <=2 h
>30 min <=2 hrs / >30 min <=2 h
Système
>30 min <=2 hrs / >30 min <=2 h
Oui
Non
Fully Recovered / Complètement rétabli
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 30-Jun-2023, a 2 year old, approximately 4.0 kilogram, neutered, male, Shih Tzu/Yorkshire Terrier crossbred dog, in unknown condition, with no known concomitant medical condition, was administered 1 tube of Hartz UltraGuard Pro Drops for Dogs 6 - 14 kg (Phenothrin (Sumithrin) / S Methoprene) via the topical route by the animal owner. This was an extra label use due to overdose. Approximately 45 minutes post application, the dog developed hyperactivity (agitation). The animal owner consulted with their veterinarian via telephone. The dog was bathed with an unknown amount of unspecified baby shampoo via the topical route by the animal owner, as directed by their veterinarian. The clinical sign resolved and the dog recovered within approximately 1 hour. No further information was received.
Mineure
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.